Clinical trial

Aspirin Dose and Atherosclerosis in Patients With Heart Disease

NCT00272337 · Florida Atlantic University, Other · Completed

Key facts

NCT number NCT00272337
Title Aspirin Dose and Atherosclerosis in Patients With Heart Disease
Official title A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)
Acronym TAD
Lead sponsor Florida Atlantic University, Other
Collaborators Bayer Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction
Intervention type Drug
Interventions Aspirin
Enrollment 37
Start date Oct 1, 2006
Primary completion Jun 1, 2009
Completion Jun 1, 2009
First posted Jan 5, 2006
Last update posted Dec 28, 2018
Countries United States

At a glance

  • 1–9 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies